Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.06 per share a year ago. These ...

As you might know, Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) just kicked off its latest second-quarter results ...

Second Quarter 2025 Financial Highlights: Total revenues for the second quarter 2025 were $154.7 million, reflecting strong ...

Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $24.4 million in its second quarter. On a per-share basis, the Princeton, New Jersey-based ...

Highlights,XTX Topco Ltd significantly increased its position in Amicus Therapeutics during the first quarter,Shares of ...

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is one of the best strong buy stocks to buy under $10. In a report released on July ...

With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases.

Amicus Therapeutics (($FOLD)) has held its Q2 earnings call. Read on for the main highlights of the call. Amicus Therapeutics’ recent earnings ...

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 Amicus Therapeutics, Inc. - GlobeNewswire - Mon Jul 21, 6:00AM CDT ...